Drug intelligence / Profile preview

taf12 shRNA

Development stage
Preclinical
Lead developer
Cold Spring Harbor Laboratory
Modality
Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous
01

Overview

Taf12 shRNA is a short hairpin RNA designed to silence the expression of TATA-box binding protein associated factor 12 (Taf12), a subunit of the TFIID co-activator complex. Research conducted at Cold Spring Harbor Laboratory demonstrated that Taf12 is essential for the maintenance of acute myeloid leukemia (AML) cells. Mechanistically, Taf12 inhibition selectively suppresses the transcription of core targets of the oncogenic transcription factor Myb. This effect is mediated through the physical interaction between the histone fold domain (HFD) dimer of Taf12/Taf4a and the transactivation domain of Myb. In preclinical models, Taf12 shRNA showed potent anti-leukemic activity in vitro and in vivo without affecting normal myeloid cells, suggesting a therapeutic window for AML treatment.

Other names
Taf12 knockdownTaf-12 knockdownTaf 12 knockdownshRNA targeting Taf12
02

Targets

TAF12 (Transcription initiation factor TFIID subunit 12 (TAF12) histone-fold domain)MYB (Proto-oncogene protein c-myb)

Beyond the preview

Go deeper on taf12 shRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on taf12 shRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call